AstraZeneca PLC (AZNCF)
USD 131.31
(-1.03%)
USD 131.31
(-1.03%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 13.28 Billion USD | 57.51% |
| 2022 | 9.08 Billion USD | 23.29% |
| 2021 | 5.11 Billion USD | -9.63% |
| 2020 | 8.08 Billion USD | 19.31% |
| 2019 | 6.71 Billion USD | -2.08% |
| 2018 | 7.11 Billion USD | 5.82% |
| 2017 | 6.62 Billion USD | -7.16% |
| 2016 | 5.96 Billion USD | 4.25% |
| 2015 | 6.96 Billion USD | 27.41% |
| 2014 | 5.49 Billion USD | -34.2% |
| 2013 | 8.34 Billion USD | -25.45% |
| 2012 | 11.19 Billion USD | -22.34% |
| 2011 | 14.41 Billion USD | -2.28% |
| 2010 | 14.74 Billion USD | 4.68% |
| 2009 | 13.94 Billion USD | 8.19% |
| 2008 | 12.61 Billion USD | 9.68% |
| 2007 | 9.95 Billion USD | 13.65% |
| 2006 | 9.56 Billion USD | 23.02% |
| 2005 | 7.82 Billion USD | 33.83% |
| 2004 | 5.81 Billion USD | 15.57% |
| 2003 | 5.3 Billion USD | 2.66% |
| 2002 | 4.96 Billion USD | -28.55% |
| 2001 | 5.01 Billion USD | 30.91% |
| 2000 | 4.91 Billion USD | 8.69% |
| 1999 | 4.49 Billion USD | 119.23% |
| 1998 | 3.24 Billion USD | 5.9% |
| 1997 | 2.24 Billion USD | 1.49% |
| 1996 | 2.15 Billion USD | 27.44% |
| 1995 | 1.35 Billion USD | 6.85% |
| 1994 | 1.47 Billion USD | 19.6% |
| 1993 | 1.37 Billion USD | 14.01% |
| 1992 | 687.06 Million USD | -28.02% |
| 1991 | 1.67 Billion USD | 22.21% |
| 1990 | 1.37 Billion USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 4.12 Billion USD | -7.67% |
| 2024 Q1 | 4.47 Billion USD | 66.44% |
| 2023 Q1 | 3.88 Billion USD | 241.65% |
| 2023 Q2 | 2.51 Billion USD | -35.21% |
| 2023 Q4 | 2.68 Billion USD | -19.42% |
| 2023 Q3 | 3.32 Billion USD | 32.04% |
| 2023 FY | - USD | 57.51% |
| 2022 FY | - USD | 23.29% |
| 2022 Q2 | 1.91 Billion USD | -12.88% |
| 2022 Q1 | 2.19 Billion USD | 832.67% |
| 2022 Q3 | 2.75 Billion USD | 44.07% |
| 2022 Q4 | 1.13 Billion USD | -58.75% |
| 2021 Q1 | 2.7 Billion USD | 81.99% |
| 2021 Q2 | 1.84 Billion USD | -31.94% |
| 2021 Q3 | 1.46 Billion USD | -20.4% |
| 2021 FY | - USD | -9.63% |
| 2021 Q4 | -300 Million USD | -120.45% |
| 2020 FY | - USD | 19.31% |
| 2020 Q3 | 2.12 Billion USD | 6.45% |
| 2020 Q4 | 1.48 Billion USD | -30.11% |
| 2020 Q2 | 2 Billion USD | -5.12% |
| 2020 Q1 | 2.1 Billion USD | 231.45% |
| 2019 Q4 | 636 Million USD | -58.51% |
| 2019 FY | - USD | -2.08% |
| 2019 Q2 | 1.22 Billion USD | -31.76% |
| 2019 Q3 | 1.53 Billion USD | 24.74% |
| 2019 Q1 | 1.8 Billion USD | 68.79% |
| 2018 Q2 | 1.47 Billion USD | 3.16% |
| 2018 FY | - USD | 5.82% |
| 2018 Q1 | 1.42 Billion USD | 97.23% |
| 2018 Q3 | 1.53 Billion USD | 4.62% |
| 2018 Q4 | 1.06 Billion USD | -30.67% |
| 2017 Q3 | 1.81 Billion USD | 16.9% |
| 2017 FY | - USD | -7.16% |
| 2017 Q1 | 1.58 Billion USD | -37.92% |
| 2017 Q2 | 1.55 Billion USD | -1.52% |
| 2017 Q4 | 723 Million USD | -60.25% |
| 2016 Q3 | 1.64 Billion USD | 82.65% |
| 2016 Q2 | 899 Million USD | -44.4% |
| 2016 Q1 | 1.61 Billion USD | 47.81% |
| 2016 FY | - USD | 4.25% |
| 2016 Q4 | 2.54 Billion USD | 54.99% |
| 2015 Q2 | 1.65 Billion USD | -7.72% |
| 2015 Q3 | 1.74 Billion USD | 5.94% |
| 2015 FY | - USD | 27.41% |
| 2015 Q4 | 1.09 Billion USD | -37.41% |
| 2015 Q1 | 1.78 Billion USD | 658.75% |
| 2014 Q3 | 1.4 Billion USD | -22.45% |
| 2014 FY | - USD | -34.2% |
| 2014 Q1 | 1.56 Billion USD | 370.42% |
| 2014 Q2 | 1.81 Billion USD | 16.25% |
| 2014 Q4 | -320 Million USD | -122.71% |
| 2013 Q1 | 2.07 Billion USD | -1.52% |
| 2013 FY | - USD | -25.45% |
| 2013 Q4 | -578 Million USD | -127.42% |
| 2013 Q3 | 2.1 Billion USD | -1.77% |
| 2013 Q2 | 2.14 Billion USD | 3.67% |
| 2012 FY | - USD | -22.34% |
| 2012 Q1 | 2.79 Billion USD | 21.72% |
| 2012 Q3 | 3.03 Billion USD | 20.86% |
| 2012 Q4 | 2.1 Billion USD | -30.63% |
| 2012 Q2 | 2.5 Billion USD | -10.18% |
| 2011 Q2 | 3.61 Billion USD | -11.12% |
| 2011 Q1 | 4.06 Billion USD | 5.64% |
| 2011 Q3 | 4.95 Billion USD | 37.26% |
| 2011 Q4 | 2.29 Billion USD | -53.75% |
| 2011 FY | - USD | -2.28% |
| 2010 Q1 | 4.17 Billion USD | 29.32% |
| 2010 Q3 | 3.13 Billion USD | -12.81% |
| 2010 FY | - USD | 4.68% |
| 2010 Q4 | 3.84 Billion USD | 22.87% |
| 2010 Q2 | 3.59 Billion USD | -14.03% |
| 2009 Q2 | 3.4 Billion USD | -6.88% |
| 2009 FY | - USD | 8.19% |
| 2009 Q3 | 3.79 Billion USD | 11.23% |
| 2009 Q1 | 3.66 Billion USD | 420.77% |
| 2009 Q4 | 3.23 Billion USD | -14.82% |
| 2008 Q3 | 3.29 Billion USD | 2.71% |
| 2008 Q4 | 703 Million USD | -78.67% |
| 2008 FY | - USD | 9.68% |
| 2008 Q2 | 3.2 Billion USD | -3.75% |
| 2008 Q1 | 3.33 Billion USD | 2264.94% |
| 2007 Q4 | -154 Million USD | -105.22% |
| 2007 Q1 | 2.86 Billion USD | 122.58% |
| 2007 Q2 | 2.95 Billion USD | 3.07% |
| 2007 FY | - USD | 13.65% |
| 2007 Q3 | 2.95 Billion USD | -0.24% |
| 2006 Q4 | 1.28 Billion USD | -51.47% |
| 2006 Q2 | 2.63 Billion USD | 7.28% |
| 2006 FY | - USD | 23.02% |
| 2006 Q1 | 2.45 Billion USD | 81.67% |
| 2006 Q3 | 2.65 Billion USD | 0.72% |
| 2005 Q4 | 1.35 Billion USD | -44.04% |
| 2005 Q3 | 2.41 Billion USD | 21.88% |
| 2005 Q2 | 1.98 Billion USD | 5.48% |
| 2005 FY | - USD | 33.83% |
| 2005 Q1 | 1.88 Billion USD | 156.9% |
| 2004 Q4 | -3.3 Billion USD | -371.65% |
| 2004 Q2 | 1.24 Billion USD | -10.1% |
| 2004 Q1 | 1.38 Billion USD | 43.48% |
| 2004 FY | - USD | 15.57% |
| 2004 Q3 | 1.21 Billion USD | -2.33% |
| 2003 Q1 | 1.56 Billion USD | 116.28% |
| 2003 FY | - USD | 2.66% |
| 2003 Q4 | 1.16 Billion USD | -39.42% |
| 2003 Q3 | 1.59 Billion USD | 48.93% |
| 2003 Q2 | 1.07 Billion USD | -31.69% |
| 2002 Q1 | 1.52 Billion USD | -59.16% |
| 2002 Q2 | 1.29 Billion USD | -19.65% |
| 2002 Q3 | 1.13 Billion USD | -8.39% |
| 2002 Q4 | 968.8 Million USD | -36.36% |
| 2002 FY | - USD | -28.55% |
| 2001 FY | - USD | 30.91% |
| 2001 Q1 | 1.3 Billion USD | -38.4% |
| 2001 Q3 | 1.22 Billion USD | 0.54% |
| 2001 Q2 | 1.15 Billion USD | -9.9% |
| 2001 Q4 | 3.44 Billion USD | 223.51% |
| 2000 Q2 | 1.23 Billion USD | 3.89% |
| 2000 FY | - USD | 8.69% |
| 2000 Q3 | 1.18 Billion USD | -4.26% |
| 2000 Q4 | 1.29 Billion USD | 76.8% |
| 2000 Q1 | 1.19 Billion USD | -29.21% |
| 1999 Q4 | -584.53 Million USD | 47.24% |
| 1999 Q3 | 1.16 Billion USD | -5.8% |
| 1999 Q2 | 1.26 Billion USD | -73.12% |
| 1999 FY | - USD | 119.23% |
| 1999 Q1 | 4.52 Billion USD | 183.46% |
| 1998 Q3 | 2.33 Billion USD | 331.52% |
| 1998 FY | - USD | 5.9% |
| 1998 Q1 | 2.41 Billion USD | 154.81% |
| 1998 Q2 | 869 Million USD | -77.66% |
| 1998 Q4 | -5.41 Billion USD | -332.5% |
| 1997 Q4 | -4.41 Billion USD | -310.08% |
| 1997 FY | - USD | 1.49% |
| 1997 Q3 | 2.09 Billion USD | -8.08% |
| 1997 Q2 | 2.28 Billion USD | 0.0% |
| 1997 Q1 | 2.28 Billion USD | 180.2% |
| 1996 Q3 | 2.31 Billion USD | 1.54% |
| 1996 FY | - USD | 27.44% |
| 1996 Q2 | 2.27 Billion USD | 0.0% |
| 1996 Q1 | 2.27 Billion USD | 147.94% |
| 1996 Q4 | -2.84 Billion USD | -223.09% |
| 1995 Q3 | 1.93 Billion USD | 459.25% |
| 1995 Q2 | 346 Million USD | -82.85% |
| 1995 FY | - USD | 6.85% |
| 1995 Q4 | -4.75 Billion USD | -345.61% |
| 1995 Q1 | 2.01 Billion USD | 150.05% |
| 1994 Q2 | 1.83 Billion USD | 0.0% |
| 1994 Q4 | -4.02 Billion USD | -329.91% |
| 1994 Q1 | 1.83 Billion USD | 147.16% |
| 1994 Q3 | 1.75 Billion USD | -4.57% |
| 1994 FY | - USD | 19.6% |
| 1993 Q1 | 1.74 Billion USD | 0.0% |
| 1993 Q3 | 1.53 Billion USD | -12.1% |
| 1993 Q4 | -3.89 Billion USD | -353.42% |
| 1993 FY | - USD | 14.01% |
| 1993 Q2 | 1.74 Billion USD | 0.0% |
| 1992 FY | - USD | -28.02% |
| 1991 FY | - USD | 9.79% |
| 1990 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bristol-Myers Squibb Company PFD CONV 2 | 19.41 Billion USD | 31.557% |
| CSPC Pharmaceutical Group Limited | 1.14 Billion USD | -1057.569% |
| Clarus Therapeutics Holdings, Inc. | -39.7 Million USD | 33570.968% |
| Novartis AG | 19.51 Billion USD | 31.91% |
| PT Kalbe Farma Tbk. | 288.13 Million USD | -4512.32% |